Jayagopal Ashwath 4
4 · Opus Genetics, Inc. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Opus Genetics CSO Jayagopal Ashwath Receives 400,000 RSUs
What Happened
Jayagopal Ashwath, Chief Scientific & Development Officer of Opus Genetics (IRD), received a grant of 400,000 restricted stock units (RSUs) on 2026-01-22. The grant is reported at $0.00 per share (typical for RSU awards) and is an equity compensation award rather than a market purchase or sale.
Key Details
- Transaction date: 2026-01-22 (Form 4 filed 2026-01-26). Filing appears timely.
- Transaction type/code: Award/Grant (code A) — 400,000 RSUs.
- Reported price: $0.00 per share; total reported acquisition value $0.
- Vesting: Per footnote, RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters (i.e., ~4 years), subject to continued service.
- Shares owned after transaction: Not specified in the provided filing.
- No 10b5-1, tax-withholding, or late-filing flags noted in the supplied information.
Context
This is a standard executive compensation grant (RSUs). RSUs convert into actual shares only as they vest and may be subject to forfeiture if the officer leaves before vesting; the $0 grant price reflects that this is an award, not a cash purchase. Such grants are common for retaining executives and do not by themselves indicate immediate buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-22+400,000→ 525,807 total
Footnotes (1)
- [F1]Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.